As a Free StocksGuide user, you can view scores for all 7,024 stocks worldwide.
11 Analysts have issued a Milestone Pharmaceuticals, Inc. forecast:
11 Analysts have issued a Milestone Pharmaceuticals, Inc. forecast:
| Jun '25 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -55 -55 |
12%
12%
|
|
| EBIT (Operating Income) EBIT | -55 -55 |
12%
12%
|
|
| Net Profit | -56 -56 |
15%
15%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Milestone Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the development and commercialization of novel small molecule therapeutics based on clinically-validated mechanisms for the treatment of cardiovascular diseases. The firm designs and develops a rapid-onset nasal spray with Etripamil. The company was founded by Philippe Douville and Philippe Lamarre in 2005 and is headquartered in Montreal, Canada.
| Head office | Canada |
| CEO | Joseph Oliveto |
| Employees | 33 |
| Founded | 2003 |
| Website | www.milestonepharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


